RAS BLOCKADE AND KIDNEY TRANSPLANT OUTCOMES

Introduction:

Renin-Angiotensin System (RAS) blockade has proven benefits in chronic kidney disease and cardiovascular disease, but studies so far have shown mixed results when used in the kidney transplant recipient population. We aimed to evaluate the impact of RAS blockade on patient and graft survival in kidney transplant recipients.

Methods:

We analysed 203 recipients who received a kidney transplant at our centre from 2012 to 2017, with follow up until 2023. The primary exposure was RAS blockade use for at least one year, with the primary endpoints of death and death censored graft failure, and secondary endpoints of estimated glomerular filtration rate and degree of albuminuria.

Results:

37% of recipients were exposed to RAS blockade for a median duration of 5 years. Mean follow up duration was 6 years. RAS blockade found to be associated with a reduction in all cause death, hazard ratio of 0.66 (95% confidence interval, 0.34-0.82).

Conclusions:

Our study found that RAS blockade was associated with better patient survival in kidney transplant recipients.

I have no potential conflict of interest to disclose.

I did not use generative AI and AI-assisted technologies in the writing process.